Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PRKDC_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PRKDC_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRKDC_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRKDC_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PRKDC_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRKDC_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PRKDC_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PRKDC_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKDC_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004227418 | Prostate | BPH | ribosomal small subunit biogenesis | 25/3107 | 73/18723 | 1.82e-04 | 1.53e-03 | 25 |
GO:000931414 | Prostate | BPH | response to radiation | 105/3107 | 456/18723 | 2.07e-04 | 1.70e-03 | 105 |
GO:00457863 | Prostate | BPH | negative regulation of cell cycle | 91/3107 | 385/18723 | 2.10e-04 | 1.71e-03 | 91 |
GO:004211010 | Prostate | BPH | T cell activation | 111/3107 | 487/18723 | 2.11e-04 | 1.72e-03 | 111 |
GO:00102127 | Prostate | BPH | response to ionizing radiation | 42/3107 | 148/18723 | 2.20e-04 | 1.78e-03 | 42 |
GO:20007363 | Prostate | BPH | regulation of stem cell differentiation | 21/3107 | 58/18723 | 2.44e-04 | 1.94e-03 | 21 |
GO:00026839 | Prostate | BPH | negative regulation of immune system process | 100/3107 | 434/18723 | 2.83e-04 | 2.20e-03 | 100 |
GO:00459303 | Prostate | BPH | negative regulation of mitotic cell cycle | 60/3107 | 235/18723 | 3.00e-04 | 2.32e-03 | 60 |
GO:00022444 | Prostate | BPH | hematopoietic progenitor cell differentiation | 34/3107 | 114/18723 | 3.08e-04 | 2.37e-03 | 34 |
GO:19031315 | Prostate | BPH | mononuclear cell differentiation | 98/3107 | 426/18723 | 3.43e-04 | 2.55e-03 | 98 |
GO:00903982 | Prostate | BPH | cellular senescence | 29/3107 | 93/18723 | 3.66e-04 | 2.71e-03 | 29 |
GO:00103325 | Prostate | BPH | response to gamma radiation | 20/3107 | 56/18723 | 4.19e-04 | 3.02e-03 | 20 |
GO:00315716 | Prostate | BPH | mitotic G1 DNA damage checkpoint | 13/3107 | 30/18723 | 5.11e-04 | 3.62e-03 | 13 |
GO:19020362 | Prostate | BPH | regulation of hematopoietic stem cell differentiation | 8/3107 | 14/18723 | 6.63e-04 | 4.46e-03 | 8 |
GO:00448196 | Prostate | BPH | mitotic G1/S transition checkpoint | 13/3107 | 31/18723 | 7.48e-04 | 4.95e-03 | 13 |
GO:00330023 | Prostate | BPH | muscle cell proliferation | 61/3107 | 248/18723 | 7.61e-04 | 5.02e-03 | 61 |
GO:00486605 | Prostate | BPH | regulation of smooth muscle cell proliferation | 47/3107 | 180/18723 | 7.63e-04 | 5.03e-03 | 47 |
GO:19019874 | Prostate | BPH | regulation of cell cycle phase transition | 89/3107 | 390/18723 | 8.17e-04 | 5.34e-03 | 89 |
GO:19028072 | Prostate | BPH | negative regulation of cell cycle G1/S phase transition | 28/3107 | 93/18723 | 8.54e-04 | 5.53e-03 | 28 |
GO:19019913 | Prostate | BPH | negative regulation of mitotic cell cycle phase transition | 46/3107 | 179/18723 | 1.24e-03 | 7.51e-03 | 46 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKDC | SNV | Missense_Mutation | | c.1855G>C | p.Asp619His | p.D619H | P78527 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
PRKDC | SNV | Missense_Mutation | novel | c.3658N>G | p.Leu1220Val | p.L1220V | P78527 | protein_coding | deleterious(0.01) | possibly_damaging(0.622) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PRKDC | SNV | Missense_Mutation | novel | c.1504N>A | p.Glu502Lys | p.E502K | P78527 | protein_coding | tolerated(0.18) | benign(0.076) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PRKDC | SNV | Missense_Mutation | novel | c.5396N>G | p.Glu1799Gly | p.E1799G | P78527 | protein_coding | tolerated(0.13) | benign(0.118) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PRKDC | SNV | Missense_Mutation | | c.9458C>G | p.Ser3153Cys | p.S3153C | P78527 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PRKDC | SNV | Missense_Mutation | novel | c.5745N>C | p.Leu1915Phe | p.L1915F | P78527 | protein_coding | deleterious(0) | probably_damaging(0.914) | TCGA-A7-A6VV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
PRKDC | SNV | Missense_Mutation | | c.2706A>T | p.Lys902Asn | p.K902N | P78527 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
PRKDC | SNV | Missense_Mutation | | c.2210N>T | p.Pro737Leu | p.P737L | P78527 | protein_coding | deleterious(0.01) | benign(0.354) | TCGA-A8-A099-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
PRKDC | SNV | Missense_Mutation | | c.6367N>T | p.Pro2123Ser | p.P2123S | P78527 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRKDC | SNV | Missense_Mutation | | c.3394N>A | p.Asp1132Asn | p.D1132N | P78527 | protein_coding | tolerated(0.21) | benign(0.055) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 252827496 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | | M9831 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | | KU-0060648 | CHEMBL1086377 | 23855836 |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 178102582 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565693 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 354702239 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 178102681 | WORTMANNIN | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | | SF1126 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565692 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 404859048 | | |